cbdMD Statistics
Total Valuation
cbdMD has a market cap or net worth of $2.65 million. The enterprise value is $4.52 million.
| Market Cap | 2.65M |
| Enterprise Value | 4.52M |
Important Dates
The next estimated earnings date is Monday, May 13, 2024, after market close.
| Earnings Date | May 13, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
cbdMD has 3.05 million shares outstanding. The number of shares has increased by 120.76% in one year.
| Shares Outstanding | 3.05M |
| Shares Change (YoY) | +120.76% |
| Shares Change (QoQ) | +46.41% |
| Owned by Insiders (%) | 21.19% |
| Owned by Institutions (%) | 8.06% |
| Float | 2.50M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | 714.29 |
| PS Ratio | 0.11 |
| Forward PS | 0.15 |
| PB Ratio | 0.38 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 0.19 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.23, with a Debt / Equity ratio of 0.48.
| Current Ratio | 1.23 |
| Quick Ratio | 0.44 |
| Debt / Equity | 0.48 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | 8,996.34 |
Financial Efficiency
Return on equity (ROE) is -141.90% and return on invested capital (ROIC) is -187.47%.
| Return on Equity (ROE) | -141.90% |
| Return on Assets (ROA) | -97.90% |
| Return on Capital (ROIC) | -187.47% |
| Revenue Per Employee | $450,876 |
| Profits Per Employee | -$461,166 |
| Employee Count | 52 |
| Asset Turnover | 0.96 |
| Inventory Turnover | 1.97 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -79.61% in the last 52 weeks. The beta is 2.09, so cbdMD's price volatility has been higher than the market average.
| Beta (1Y) | 2.09 |
| 52-Week Price Change | -79.61% |
| 50-Day Moving Average | 0.83 |
| 200-Day Moving Average | 0.93 |
| Relative Strength Index (RSI) | 46.60 |
| Average Volume (30 Days) | 264,808 |
Short Selling Information
The latest short interest is 226,406, so 7.44% of the outstanding shares have been sold short.
| Short Interest | 226,406 |
| Short Previous Month | 244,191 |
| Short % of Shares Out | 7.44% |
| Short % of Float | 9.07% |
| Short Ratio (days to cover) | 0.32 |
Income Statement
In the last 12 months, cbdMD had revenue of $23.45 million and -$23.98 million in losses. Loss per share was -$12.63.
| Revenue | 23.45M |
| Gross Profit | 14.97M |
| Operating Income | -19.51M |
| Pretax Income | -19.98M |
| Net Income | -23.98M |
| EBITDA | -17.13M |
| EBIT | -19.98M |
| Loss Per Share | -$12.63 |
Balance Sheet
The company has $1.50 million in cash and $3.37 million in debt, giving a net cash position of -$1.86 million or -$0.61 per share.
| Cash & Cash Equivalents | 1.50M |
| Total Debt | 3.37M |
| Net Cash | -1.86M |
| Net Cash Per Share | -$0.61 |
| Equity / Book Value | 7.04M |
| Book Value Per Share | 2.31 |
| Working Capital | 1.39M |
Cash Flow
In the last 12 months, operating cash flow was -$2.34 million and capital expenditures -$304,814, giving a free cash flow of -$2.65 million.
| Operating Cash Flow | -2.34M |
| Capital Expenditures | -304,814 |
| Free Cash Flow | -2.65M |
| FCF Per Share | -$0.89 |
Margins
Gross margin is 63.84%, with operating and profit margins of -83.20% and -102.28%.
| Gross Margin | 63.84% |
| Operating Margin | -83.20% |
| Pretax Margin | -85.21% |
| Profit Margin | -102.28% |
| EBITDA Margin | -73.08% |
| EBIT Margin | -85.22% |
| FCF Margin | -11.30% |
Dividends & Yields
cbdMD does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -120.76% |
| Shareholder Yield | -120.76% |
| Earnings Yield | -904.05% |
| FCF Yield | -99.84% |
Analyst Forecast
The average price target for cbdMD is $3.00, which is 240.91% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $3.00 |
| Price Target Difference | 240.91% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 1 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock Splits
The last stock split was on April 25, 2023. It was a reverse split with a ratio of 1:45.
| Last Split Date | Apr 25, 2023 |
| Split Type | Reverse |
| Split Ratio | 1:45 |
Scores
cbdMD has an Altman Z-Score of -18.86 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -18.86 |
| Piotroski F-Score | 3 |